Taisho Pharmaceutical Co Ltd in Consumer Health

Company Profile

About This Report

Sep 2011

Taisho remains a leading consumer health producer, but it continues to rely almost exclusively on the Japanese market. Recent moves to diversify outside of Japan include the 2009 acquisition of some Bristol-Myers Squibb analgesics brands in Asia Pacific, as well as the 2011 acquisition of Hoe Pharmaceuticals based in Malaysia. Although these acquisitions represent a move in the right direct, further action is needed to diversify its geographic reach.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Taisho Pharmaceutical Co Ltd in Consumer Health

Euromonitor International's report on Taisho Pharmaceutical Co Ltd delivers a detailed strategic analysis of the company's business, examining its performance in the Vitamins and Dietary Supplements market and the global economy.

Company and market share data provide a detailed look at the financial position of Taisho Pharmaceutical Co Ltd, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of Taisho Pharmaceutical Co Ltd.

This report examines:
  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWOT analysis of Taisho Pharmaceutical Co Ltd provides strategic intelligence on:
  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research You Can Trust:

Euromonitor International's company profile reports are written by our Vitamins and Dietary Supplements research team, a dedicated group of analysts that knows the industry inside and out.

Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Delivery format

Reports are delivered in PDF format and can be downloaded from your online account immediately after purchase.

Introduction

Scope

Strategic Evaluation

Taisho: Japanese Focus
Financial analysis: Fiscal 2010
Taisho 2011 forecasts
SWOT: Taisho Pharmaceutical Co Ltd
Strategic objectives and challenges

Competitive Positioning

Reliance on Japan holds back Taisho
Japanese fortunes influence Taisho’s performance
Johnson & Johnson leads pack despite recalls

Market Assessment

Taisho: strong presence in tonics and bottled nutritive drinks
Asia Pacific still offers strongest opportunities for Taisho

Geographic and Category Opportunities

Leverage Hoe acquisition to bring Taisho brands to Malaysia
Indonesia: Cross-border opportunities in consumer health
Lipovitan vulnerable to declines in Japanese market
Develop Lipovitan beauty tonic and bottled nutritive drink
Pan-Asia Pacific expansion should be Taisho’s priority
Consider expansion into medicated confectionery and generics
Consider expansion in analgesics through acquisition
Poor outlook in Japan analgesics
Hoe: A new armoury of tools for Taisho in medicated skin care
Taisho well positioned in hair loss treatments
Opportunities in medicated skin care

Brand Strategy

International expansion for Lipovitan crucial
Pabron: Potential for growth

Operations

Distribution strategy and manufacturing facilities

Recommendations

International expansion should remain the priority